Pediatric asthma pharmacotherapy has two main goals: to address underlying airway inflammation and to promote bronchodilation. Physicians use two types of therapy to achieve these goals—maintenance therapy (e.g., a LABA/ICS, such as GSK’s Advair or AstraZeneca’s Symbicort) and rescue therapy (e.g., a SABA, such as albuterol)—and most pediatric asthma patients receive more than one drug to treat their condition. Maintenance and rescue therapy for pediatric asthma consists of established agents; however, the first branded-generic LABA/ICS FDC (Teva’s AirDuo and its generic), the first LAMA (BI’s Spiriva), and several novel biologics (e.g., GSK’s Nucala) were recently added to the arsenal of drugs to treat pediatric asthma. The availability of these and other agents will expand physicians’ choice of treatments and fuel increasing competition in the asthma therapy market.
Key Drugs Covered
Key Analysis Provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.